The DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma
Open accessAbstract
Background Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL.Patients and methods Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [(18)F]FDG-PET scan at midtreatment. Presence or absence of abnormal [(18)F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [(18)F]FDG-PET findings on PFS and OS.Results At midtreatment, 33 patients showed persistent abnormal [(18)F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [(18)F]FDG-PET findings and PFS (P <1 x 10(-5)) and OS (P <1 x 10(-5)). In multivariate analysis, [(18)F]FDG-PET at midtreatment was a stronger prognostic factor for PFS (P <1 x 10(-7)) and OS (P <9 x 10(-6)) than the IPI (P <0.11 and P <0.03, respectively).Conclusions Early restaging [(18)F]FDG-PET may be used to tailor induction chemotherapy in patients with aggressive NHL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“several recent studies have shown that enhanced glycolysis is a distinctive marker of cancer progression (4,5)”
From Glycolytic Enzymes Can Modulate Cellular Life Span (2005) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Harris, N. L., Jaffe, E., Stein, H., Pm, B., Jk, C., Cleary, M. L., Delsol, G., Peeters, C., Falini, B., & Gatter, K. C. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,312
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,950
Maximum Likelihood Reconstruction for Emission Tomography
Shepp, L. A., & Vardi, Y. (1982) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.1982.4307558 · Cited by 4,429
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
Jérusalem, G., Beguin, Y. P., Fassotte, M., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 562
Research works printed but not linked: 1
- 2000, The first international symposium on biology and treatment of aggressive lymphomas. The stagnation seems to be over, Ann Hematol 2001, 80, B1
Cited by
Sorted by citations
Items 401–410 of 410
Mohnike, W., Hör, G., & Hertel, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48842-3_11
Mohnike, W., Hör, G., & Schelbert, H. R. (2008) · Springer eBooks · doi:10.1007/978-3-540-74091-9_9
Straus, D. J., & Kumar, A. J. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm119.pub2
Damlaj, M., Jaber, W., Alnajjar, A., Altamimi, S., Onazi, T. A., Alzayed, M. F., Damlaj, A., Yassin, R., Alahmari, B., Alhejazi, A., et al. (2023) · Current Research in Translational Medicine · doi:10.1016/j.retram.2023.103406
Future Directions in Aggressive Lymphomas
Perini, G. F., & Fayad, L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5851-7_10
FDG-PET in Lymphoma: The Deauville Era and Beyond.
Thakur, P. B., & Basu, S. (2026) · PET Clinics · doi:10.1016/j.cpet.2026.06.006
Shafey, M., Keating, M., Owen, C., Balitsky, A. K., Bosch, M. J., Fleury, I., Forward, N. A., Kansara, R. R., Lemieux, C., Macdonald, D. A., et al. (2026) · Current Oncology · doi:10.3390/curroncol33110644
Critères des réponses thérapeutiques TEP dans les hémopathies lymphoïdes
Cuenca, X., & Filmont, J. (2008) · ONCOLOGIE · doi:10.1007/s10269-008-0883-6
Identifying response to therapy in longitudinal PET imaging studies
Phillips, M. R. (2014) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Metadata
- Authors
- Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Spaepen, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 13
- Issue
- 9
- Pages
- 1356-1363
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W1990827442
- Cited by
- 410
- References
- 30
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 3 · 2022: 11 · 2021: 7 · 2020: 6 · 2019: 4 · 2018: 2 · 2017: 15 · 2016: 18 · 2015: 17 · 2014: 14 · 2013: 25 · 2012: 25
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fonds Wetenschappelijk Onderzoek
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Hematology › Hematological disorders and diagnostics
- Keywords
- aggressive non-Hodgkin lymphoma, 18F-FDG PET, treatment response prediction, progression-free survival, overall survival, International Prognostic Index, complete remission, prognostic factors, treatment response monitoring
- MeSH terms
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Cyclophosphamide, Doxorubicin, Evaluation Studies as Topic, Female, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Monitoring, Physiologic, Neoplasm Staging, Predictive Value of Tests, Prednisolone, Probability, Prognosis, Prospective Studies, Sensitivity and Specificity, Time Factors, Tomography, Emission-Computed, Vincristine, Survival Rate, Multivariate Analysis, Treatment Outcome, Fluorodeoxyglucose F18
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
